China is one of the largest growing economies in the world today. With an increasing middle class and the government dedicated to improving the quality of healthcare, many Chinese VC, PE and public companies are looking for investment, M&A and in-licensing opportunities in the US. Significant opportunities exist for US pharmaceutical and medtech companies willing to invest the time and resources in the coming years. Join this timely, lively, blue ribbon panel of experts as we discuss the China biopharma and medtech landscape, healthcare structure and funding opportunities for US companies from China investors. Ask questions and contribute your insights during the audience interactive segment.

Keynote Speaker: Sean Cao, Ph.D., MBA, Managing Director, C-Bridge Capital
Dr. Cao is the Managing Director of C-Bridge Capital, a healthcare VC fund based in China with $700M AUM.